2025-2031 Global Ustekinumab Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > 2025-2031 Global Ustekinumab Industry Research & Trends Analysis Report

2025-2031 Global Ustekinumab Industry Research & Trends Analysis Report

Publication Date: 2025-08-19
Report Id: 2363989
Industry: Pharma & Healthcare
Report Page: 138
Chart: 138

PDF Download

Publication Date: 2025-08-19
Report Id: 2363989
Industry: Pharma & Healthcare
Report Page: 138
Chart: 138

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Ustekinumab Definition
1.2 Global Ustekinumab Market Size and Forecast
1.2.1 By Revenue, Global Ustekinumab Market Size, 2020-2031
1.2.2 By Sales Volume, Global Ustekinumab Market Size, 2020-2031
1.2.3 Global Ustekinumab Price Trend, 2020-2031
1.3 China Ustekinumab Market Size and Forecast
1.3.1 By Revenue, China Ustekinumab Market Size, 2020-2031
1.3.2 By Sales Volume, China Ustekinumab Market Size, 2020-2031
1.3.3 China Ustekinumab Price Trend, 2020-2031
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Ustekinumab Share in Global Market, 2020-2031
1.4.2 By Sales Volume, China Ustekinumab Share in Global Market, 2020-2031
1.4.3 Ustekinumab Market Size: China VS Global, 2020-2031
1.5 Ustekinumab Market Dynamics
1.5.1 Ustekinumab Market Drivers
1.5.2 Ustekinumab Market Restraints
1.5.3 Ustekinumab Industry Trends
1.5.4 Ustekinumab Industry Policy

2 Global Competitive Landscape by Company
2.1 Global Ustekinumab Revenue by Company, 2020-2025
2.2 Global Ustekinumab Sales Volume by Company, 2020-2025
2.3 Global Ustekinumab Price by Company, 2020-2025
2.4 Global Ustekinumab Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Ustekinumab Concentration Ratio
2.6 Global Ustekinumab Mergers & Acquisitions, Expansion Plans
2.7 Global Ustekinumab Manufacturers Product Type

3 China Competitive Landscape by Company
3.1 China Ustekinumab Revenue by Company, 2020-2025
3.2 China Ustekinumab Sales Volume by Company, 2020-2025
3.3 China Ustekinumab Ustekinumab Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.4 China Ustekinumab Market, Sales Percentage of Local Players VS Foreign Players (2020-2025)
3.5 Chinese Local Players, Ustekinumab Domestic VS Export
3.6 China Market, Ustekinumab Import & Export
3.6.1 China Market, Ustekinumab Import & Export, 2020-2031
3.6.2 China Ustekinumab Import & Export Trends
3.6.3 Main Sources of China Ustekinumab Import
3.6.4 Export Destination of China Ustekinumab

4 Ustekinumab Production by Region
4.1 Global Ustekinumab Capacity, Production and Capacity Utilization, 2020-2031
4.2 Global Geographic Distribution of Ustekinumab Manufacturers
4.3 Global Major Manufacturers, Ustekinumab Capacity Expansion and Future Plans
4.4 Global Ustekinumab Capacity by Region
4.5 Global Ustekinumab Production by Region
4.5.1 Global Ustekinumab Production & Forecast by Region, 2020 VS 2024 VS 2031
4.5.2 Global Ustekinumab Production by Region, 2020-2025
4.5.3 Global Ustekinumab Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 Ustekinumab Industry Chain
5.2 Ustekinumab Upstream Analysis
5.2.1 Ustekinumab Core Raw Materials
5.2.2 Main Manufacturers of Ustekinumab Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Ustekinumab Production Mode
5.6 Ustekinumab Procurement Model
5.7 Ustekinumab Industry Sales Model and Sales Channels
5.7.1 Ustekinumab Sales Model
5.7.2 Ustekinumab Typical Distributors

6 Sights by Type
6.1 Ustekinumab Classification
6.1.1 Intravenous
6.1.2 Subcutaneous
6.2 by Type, Global Ustekinumab Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global Ustekinumab Revenue, 2020-2031
6.4 by Type, Global Ustekinumab Sales Volume, 2020-2031
6.5 by Type, Global Ustekinumab Price, 2020-2031

7 Sights by Application
7.1 Ustekinumab Segment by Application
7.1.1 Plaque Psoriasis
7.1.2 Psoriatic Arthritis
7.1.3 Crohn’s Disease
7.1.4 Ulcerative Colitis
7.1.5 Others
7.2 by Application, Global Ustekinumab Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Application, Global Ustekinumab Revenue, 2020-2031
7.4 by Application, Global Ustekinumab Sales Volume, 2020-2031
7.5 by Application, Global Ustekinumab Price, 2020-2031

8 Sales Sights by Region
8.1 By Region, Global Ustekinumab Market Size, 2020 VS 2024 VS 2031
8.2 By Region, Global Ustekinumab Revenue, 2020-2031
8.3 By Region, Global Ustekinumab Sales Volume, 2020-2031
8.4 North America
8.4.1 North America Ustekinumab Market Size & Forecasts, 2020-2031
8.4.2 By Country, North America Ustekinumab Market Size Market Share
8.5 Europe
8.5.1 Europe Ustekinumab Market Size & Forecasts, 2020-2031
8.5.2 By Country, Europe Ustekinumab Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific Ustekinumab Market Size & Forecasts, 2020-2031
8.6.2 By Country/Region, Asia Pacific Ustekinumab Market Size Market Share
8.7 South America
8.7.1 South AmericaUstekinumab Market Size & Forecasts, 2020-2031
8.7.2 By Country, South America Ustekinumab Market Size Market Share
8.8 Middle East & Africa

9 Sales Sights by Country Level
9.1 By Country, Global Ustekinumab Market Size & CAGR，2020 VS 2024 VS 2031
9.2 By Country, Global Ustekinumab Revenue, 2020-2031
9.3 By Country, Global Ustekinumab Sales Volume, 2020-2031
9.4 United States
9.4.1 United States Ustekinumab Market Size, 2020-2031
9.4.2 By Company, United States Ustekinumab Sales Volume Market Share, 2024
9.4.3 by Type, United States Ustekinumab Market Size, Share, 2024 VS 2031
9.4.4 by Application, United States Ustekinumab Market Size, Share, 2024 VS 2031
9.5 Europe
9.5.1 Europe Ustekinumab Market Size, 2020-2031
9.5.2 By Company, Europe Ustekinumab Sales Volume Market Share, 2024
9.5.3 by Type, Europe Ustekinumab Market Size, Share, 2024 VS 2031
9.5.4 by Application, Europe Ustekinumab Market Size, Share, 2024 VS 2031
9.6 China
9.6.1 China Ustekinumab Market Size, 2020-2031
9.6.2 By Company, China Ustekinumab Sales Volume Market Share, 2024
9.6.3 by Type, China Ustekinumab Market Size, Share, 2024 VS 2031
9.6.4 by Application, China Ustekinumab Market Size, Share, 2024 VS 2031
9.7 Japan
9.7.1 Japan Ustekinumab Market Size, 2020-2031
9.7.2 By Company, Japan Ustekinumab Market Share, 2024
9.7.3 by Type, Japan Ustekinumab Market Size, Share, 2024 VS 2031
9.7.4 by Application, Japan Ustekinumab Market Size, Share, 2024 VS 2031
9.8 South Korea
9.8.1 South Korea Ustekinumab Market Size, 2020-2031
9.8.2 By Company, South Korea Ustekinumab Market Share, 2024
9.8.3 by Type, South Korea Ustekinumab Market Size, Share, 2024 VS 2031
9.8.4 by Application, South Korea Ustekinumab Market Size, Share, 2024 VS 2031
9.9 Southeast Asia
9.9.1 Southeast Asia Ustekinumab Market Size, 2020-2031
9.9.2 By Company, Southeast Asia Ustekinumab Market Share, 2024
9.9.3 by Type, Southeast Asia Ustekinumab Market Size, Share, 2024 VS 2031
9.9.4 by Application, Southeast Asia Ustekinumab Market Size, Share, 2024 VS 2031
9.10 India
9.10.1 India Ustekinumab Market Size, 2020-2031
9.10.2 By Company, India Ustekinumab Market Share, 2024
9.10.3 by Type, India Ustekinumab Market Size, Share, 2024 VS 2031
9.10.4 by Application, India Ustekinumab Market Size, Share, 2024 VS 2031
9.11 Middle East & Africa
9.11.1 Middle East & Africa Ustekinumab Market Size, 2020-2031
9.11.2 By Company, Middle East & Africa Ustekinumab Market Share, 2024
9.11.3 by Type, Middle East & Africa Ustekinumab Market Size, Share, 2024 VS 2031
9.11.4 by Application, Middle East & Africa Ustekinumab Market Size, Share, 2024 VS 2031

10 Manufacturers Profile
10.1 Meiji
10.1.1 Meiji Company Information, Head Office, Market Area, and Industry Position
10.1.2 Meiji Ustekinumab Models, Specifications, and Application
10.1.3 Meiji Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.1.4 Meiji Company Profile and Main Business
10.1.5 Meiji Recent Developments
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
10.2.2 Johnson & Johnson Ustekinumab Models, Specifications, and Application
10.2.3 Johnson & Johnson Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.2.4 Johnson & Johnson Company Profile and Main Business
10.2.5 Johnson & Johnson Recent Developments
10.3 Alvotech
10.3.1 Alvotech Company Information, Head Office, Market Area, and Industry Position
10.3.2 Alvotech Ustekinumab Models, Specifications, and Application
10.3.3 Alvotech Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.3.4 Alvotech Company Profile and Main Business
10.3.5 Alvotech Recent Developments
10.4 Fuji Pharma
10.4.1 Fuji Pharma Company Information, Head Office, Market Area, and Industry Position
10.4.2 Fuji Pharma Ustekinumab Models, Specifications, and Application
10.4.3 Fuji Pharma Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.4.4 Fuji Pharma Company Profile and Main Business
10.4.5 Fuji Pharma Recent Developments
10.5 Mitsubishi Tanabe
10.5.1 Mitsubishi Tanabe Company Information, Head Office, Market Area, and Industry Position
10.5.2 Mitsubishi Tanabe Ustekinumab Models, Specifications, and Application
10.5.3 Mitsubishi Tanabe Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.5.4 Mitsubishi Tanabe Company Profile and Main Business
10.5.5 Mitsubishi Tanabe Recent Developments
10.6 Stada
10.6.1 Stada Company Information, Head Office, Market Area, and Industry Position
10.6.2 Stada Ustekinumab Models, Specifications, and Application
10.6.3 Stada Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.6.4 Stada Company Profile and Main Business
10.6.5 Stada Recent Developments
10.7 EPIRUS BioPharma
10.7.1 EPIRUS BioPharma Company Information, Head Office, Market Area, and Industry Position
10.7.2 EPIRUS BioPharma Ustekinumab Models, Specifications, and Application
10.7.3 EPIRUS BioPharma Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.7.4 EPIRUS BioPharma Company Profile and Main Business
10.7.5 EPIRUS BioPharma Recent Developments
10.8 Formycon
10.8.1 Formycon Company Information, Head Office, Market Area, and Industry Position
10.8.2 Formycon Ustekinumab Models, Specifications, and Application
10.8.3 Formycon Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.8.4 Formycon Company Profile and Main Business
10.8.5 Formycon Recent Developments
10.9 NeuClone
10.9.1 NeuClone Company Information, Head Office, Market Area, and Industry Position
10.9.2 NeuClone Ustekinumab Models, Specifications, and Application
10.9.3 NeuClone Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.9.4 NeuClone Company Profile and Main Business
10.9.5 NeuClone Recent Developments
10.10 Bio-Thera Solutions
10.10.1 Bio-Thera Solutions Company Information, Head Office, Market Area, and Industry Position
10.10.2 Bio-Thera Solutions Ustekinumab Models, Specifications, and Application
10.10.3 Bio-Thera Solutions Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.10.4 Bio-Thera Solutions Company Profile and Main Business
10.10.5 Bio-Thera Solutions Recent Developments
10.11 Huadong Medicine
10.11.1 Huadong Medicine Company Information, Head Office, Market Area, and Industry Position
10.11.2 Huadong Medicine Ustekinumab Models, Specifications, and Application
10.11.3 Huadong Medicine Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.11.4 Huadong Medicine Company Profile and Main Business
10.11.5 Huadong Medicine Recent Developments
10.12 Amgen
10.12.1 Amgen Company Information, Head Office, Market Area, and Industry Position
10.12.2 Amgen Ustekinumab Models, Specifications, and Application
10.12.3 Amgen Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.12.4 Amgen Company Profile and Main Business
10.12.5 Amgen Recent Developments
10.13 Sandoz
10.13.1 Sandoz Company Information, Head Office, Market Area, and Industry Position
10.13.2 Sandoz Ustekinumab Models, Specifications, and Application
10.13.3 Sandoz Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.13.4 Sandoz Company Profile and Main Business
10.13.5 Sandoz Recent Developments
10.14 Biocon Biologics
10.14.1 Biocon Biologics Company Information, Head Office, Market Area, and Industry Position
10.14.2 Biocon Biologics Ustekinumab Models, Specifications, and Application
10.14.3 Biocon Biologics Ustekinumab Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.14.4 Biocon Biologics Company Profile and Main Business
10.14.5 Biocon Biologics Recent Developments

11 Conclusion

12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer

According to YH Research, the global market for Ustekinumab should grow from US$ million in 2024 to US$ million by 2031, with a CAGR of %for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

Ustekinumab is a fully human IgG1κ monoclonal antibody that specifically binds to the p40 protein subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their interaction with cell surface receptors and suppressing related inflammatory responses. It is indicated for the treatment of immune-mediated disorders such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the production volume of ustekinumab was 6.12 million syringes, with an average price of USD 3,566 per syringe.

Market Overview
From 2024 to 2025 the ustekinumab landscape has pivoted to multi-biosimilar competition: the EU moved first in January 2024 (Uzpruvo by STADA/Alvotech), Japan approvals were in place since 2023 (Fuji Pharma with Alvotech), China granted its first domestic approval in October 2024 (Huadong Medicine/QX001S), and the U.S. became a crowded arena in 1H25 with several launches (Selarsdi by Teva/Alvotech, Otulfi by Fresenius Kabi/Formycon, Imuldosa by Dong-A ST/Meiji/Accord, and Starjemza by Hikma/Bio-Thera). J&J’s ex-U.S. Stelara sales started to feel intensified pressure as biosimilars expanded geographically.

Regional Structure
Based on approval/launch timing, access dynamics and the originator’s disclosed regional trends, the estimated 1H25 revenue split for ustekinumab (originator + biosimilars) is: United States 62%, Europe 18%, Japan 7%, China 5%, Rest of World 8% (summing to 100%). The EU’s early 2024 launches reduced the originator’s share, the U.S. turned competitive in 2025 with interchangeable products and dual IV/SC formulations, while Japan and China—despite approvals—remain smaller in absolute value versus the U.S. This estimate is anchored to J&J’s regional sales structure and the actual approval/launch cadence.

Key Manufacturers & Competition
Active players include the originator Johnson & Johnson; biosimilar entrants Teva/Alvotech (Selarsdi; interchangeable), STADA/Alvotech (Uzpruvo in the EU), Fresenius Kabi/Formycon (Otulfi; interchangeable; IV and SC), Dong-A ST/Meiji/Accord (Imuldosa; US/EU approvals with UK/IE launches), Hikma/Bio-Thera (Starjemza; US), plus Fuji Pharma (Japan commercialization with Alvotech) and Huadong Medicine (first domestic approval in China). Competition is driven by interchangeability, full-route coverage (SC + IV), industrial scale/release cycle, and access/contracting speed. NeuClone remains earlier-stage; EPIRUS BioPharma has no recent authoritative disclosures tied to this asset.

Technology Trends & Innovation
The focus is on tight analytical/clinical matching plus differentiation via “interchangeability,” full-formulation portfolios (SC and IV), high-concentration prefilled devices/auto-injectors, and robust global CMC/release networks. Otulfi’s interchangeable designation with both IV and SC underscores the advantage of complete modality coverage; Alvotech’s centralized Reykjavik manufacturing combined with regional commercialization partners exemplifies a “central-make, local-sell” operating model.

Policy & Growth Drivers
Clear regulatory pathways and frequent approvals across the U.S./EU/Japan, together with Europe’s procurement-driven uptake and the U.S. patent expiry in 2025, are elevating price competition and substitution rates. China’s first domestic approval in 2024 and subsequent indication filings improve affordability and access. In Japan, coordinated promotion arrangements (e.g., with Mitsubishi Tanabe) remain relevant during the transition.

This report aims to provide a comprehensive study of the global market for Ustekinumab.
Report Highlights:
(1) Global Ustekinumab market size (sales volume & revenue), history data from 2020-2025, and forecast data from 2026 to 2031.

(2) Global Ustekinumab market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(3) China Ustekinumab market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(4) Global Ustekinumab segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Ustekinumab segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Global major production regions of Ustekinumab, capacity, production and trends.

(7) Ustekinumab industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
Intravenous
Subcutaneous

Market segment by Application, can be divided into
Plaque Psoriasis
Psoriatic Arthritis
Crohn’s Disease
Ulcerative Colitis
Others

Market segment by players, this report covers
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
Stada
EPIRUS BioPharma
Formycon
NeuClone
Bio-Thera Solutions
Huadong Medicine
Amgen
Sandoz
Biocon Biologics